Homeland Nickel Inc (SHL) Fair Value & Analysis
Healthcare · CA · Market cap A$9.6B
Fair value as of: Jun 25, 2026
From 24 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from A$49.45 to A$22.86 (−53.8%) since Jun 24, 2026. Share price +8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range A$17.86 – A$26.83 · fair‑value band A$17.15 – A$28.58 · the A$19.83 price screens below the A$22.86 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Homeland Nickel Inc (SHL) currently trades at A$19.83, while our model-based Fair Value estimate is A$22.86 — implying the stock looks roughly 15.3% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Homeland Nickel Inc generated revenue of A$10.4B at a net margin of 5.2%. Revenue grew 16.6% year over year. It earns a return on equity of 6.6%. Net debt stands at A$4.5B. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Homeland Nickel Inc., together with its subsidiaries, engages in the acquisition, exploration, evaluation, and development of mineral properties in Canada and the United States. It explores for copper, gold, and nickel deposits. The company was formerly known as Spruce Ridge Resources Ltd. and changed its name to Homeland Nickel Inc. in May 2024. Homeland Nickel Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Homeland Nickel Inc reported revenue of A$9.6B in FY2025 versus A$8.8B in FY2021, a compound +2.5%/yr. Reported net income was A$514M in FY2025, compounding −20.9%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $186.64 | $85.95 | -54% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Homeland Nickel Inc (SHL) undervalued?
What is the fair value of SHL?
What is the quality score of SHL?
What is the revenue of Homeland Nickel Inc (SHL)?
What is the net profit margin of SHL?
Does Homeland Nickel Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.